R1 RCM Inc.

DB:6HL0 Stock Report

Market Cap: €5.7b

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

R1 RCM Valuation

Is 6HL0 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 6HL0 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 6HL0 (€13.4) is trading below our estimate of fair value (€54.36)

Significantly Below Fair Value: 6HL0 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6HL0?

Key metric: As 6HL0 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 6HL0. This is calculated by dividing 6HL0's market cap by their current revenue.
What is 6HL0's PS Ratio?
PS Ratio2.5x
SalesUS$2.46b
Market CapUS$6.04b

Price to Sales Ratio vs Peers

How does 6HL0's PS Ratio compare to its peers?

The above table shows the PS ratio for 6HL0 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.8x
FME Fresenius Medical Care
0.6x3.8%€12.4b
SYAB SYNLAB
1x4.4%€2.5b
FRE Fresenius SE KGaA
0.8x3.6%€18.8b
V3V VITA 34
0.9x2.9%€72.5m
6HL0 R1 RCM
2.5x12.2%€6.0b

Price-To-Sales vs Peers: 6HL0 is expensive based on its Price-To-Sales Ratio (2.5x) compared to the peer average (0.8x).

Price to Sales Ratio vs Industry

How does 6HL0's PS Ratio compare vs other companies in the DE Healthcare Industry?

1 CompanyPrice / SalesEstimated GrowthMarket Cap
TLIK Arzneiwerk VIDA
0.08xn/aUS$4.67m
No more companies available in this PS range
6HL0 2.5xIndustry Avg. 0.6xNo. of Companies3PS00.40.81.21.62+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 6HL0 is expensive based on its Price-To-Sales Ratio (2.5x) compared to the European Healthcare industry average (0.6x).

Price to Sales Ratio vs Fair Ratio

What is 6HL0's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6HL0 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.5x
Fair PS Ratio1.2x

Price-To-Sales vs Fair Ratio: 6HL0 is expensive based on its Price-To-Sales Ratio (2.5x) compared to the estimated Fair Price-To-Sales Ratio (1.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 6HL0 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€13.40
€13.99
+4.4%
10.0%€17.93€13.50n/a9
Nov ’25€13.00
€13.45
+3.4%
9.3%€17.38€12.81n/a11
Oct ’25€12.60
€13.46
+6.8%
8.6%€17.41€12.83n/a13
Sep ’25€12.60
€13.46
+6.8%
8.6%€17.41€12.83n/a13
Aug ’25€11.80
€14.48
+22.7%
11.6%€18.53€12.97n/a14
Jul ’25€11.60
€15.48
+33.5%
11.8%€18.69€13.08n/a14
Jun ’25€11.90
€15.47
+30.0%
11.5%€18.44€12.91n/a14
May ’25€11.40
€15.59
+36.8%
10.6%€18.42€12.90n/a14
Apr ’25€12.10
€15.84
+30.9%
8.5%€18.42€13.82n/a15
Mar ’25€12.90
€15.79
+22.4%
9.4%€18.50€12.95n/a16
Feb ’25€9.30
€14.86
+59.8%
15.8%€18.38€10.11n/a17
Jan ’25€9.55
€15.82
+65.7%
18.2%€23.85€10.09n/a16
Dec ’24€9.55
€16.63
+74.2%
14.5%€23.90€12.87n/a16
Nov ’24€11.40
€20.17
+76.9%
9.6%€24.50€16.96€13.0016
Oct ’24€14.10
€20.08
+42.4%
9.3%€24.42€16.91€12.6017
Sep ’24€15.70
€19.61
+24.9%
9.3%€23.84€16.51€12.6017
Aug ’24€15.50
€18.30
+18.0%
12.3%€23.64€14.55€11.8016
Jul ’24€16.60
€18.46
+11.2%
12.4%€23.92€14.72€11.6016
Jun ’24€15.00
€17.99
+19.9%
12.2%€24.07€14.81€11.9016
May ’24€13.80
€17.18
+24.5%
13.6%€23.67€13.65€11.4016
Apr ’24€13.60
€17.48
+28.5%
15.0%€23.97€13.83€12.1013
Mar ’24€13.20
€17.07
+29.3%
18.6%€24.31€10.29€12.9014
Feb ’24€13.20
€13.98
+5.9%
21.4%€22.76€10.01€9.3014
Jan ’24€10.10
€13.32
+31.9%
25.7%€23.79€9.51€9.5513
Dec ’23€8.40
€13.12
+56.2%
29.4%€24.22€9.69€9.5511
Nov ’23€17.70
€30.83
+74.2%
10.8%€35.12€25.08€11.4011

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Shandong Weigao Group Medical Polymer

HK$20.1b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.52

7D

-8.8%

1Y

-37.3%

LNA Santé

€244.4m

Engages in the management and operation of health establishments.

2N3

€23.25

7D

-5.5%

1Y

18.9%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

7D

0.5%

1Y

-82.5%